Clinical Trial Findings will Shape Treatments for Cardiovascular Disease
NEW YORK, NY - August 5, 2010 - The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. Findings from these clinical trials are expected to significantly impact interventional cardiology practices and patient care. TCT 2010 will take place September 21 - 25 in Washington, DC.
The studies selected will shed new light on the effectiveness of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent heart disease, one of the leading causes of death globally.
Late-breaking clinical trials and first report investigations will be highlighted during press conferences scheduled for Thursday, September 23, Friday, September 24, and Saturday, September 25.
THURSDAY, SEPTEMBER 23
Late Breaking Trials
PARTNER: A Prospective Randomized Trial of Transcatheter Aortic Valve Implantation Compared to Standard Therapy in Patients with Inoperable Aortic Stenosis
SPIRIT IV: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
COMPARE: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
First Report Investigations
LANCELOT ACS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Acute Coronary Syndromes
LEVANT I: A Prospective Randomized Trial of a Paclitaxel-Eluting Balloon Compared to a Non-Drug-Eluting Balloon With and Without Stenting in Patients with Diseased Femoropopliteal Arteries
PERfECT STENT: A Prospective Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients Treated with Endothelial Progenitor Cell Capturing Stents for De Novo Coronary Artery Disease
FRIDAY, SEPTEMBER 24
Late Breaking Trials
ZILVER PTX: A Prospective Randomized Trial of a Paclitaxel-Eluting Stent Compared to Balloon Angioplasty with Provisional Bare Metal Stenting in Patients with Superficial Femoral Artery Disease
SORT OUT 4: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
ISAR-TEST-4: Two-Year Clinical and Angiographic Outcomes from a Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
First Report Investigations
DES-BTK: A Prospective, Double-Blind, Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease
TORPEDO: A Prospective Randomized Trial of Percutaneous Endovenous Intervention Compared to Anticoagulation Alone in Patients with Deep Venous Thrombosis
BLAST: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Monocyte-Depleting Agent After Bare Metal Stents in Patients with Coronary Artery Disease
SATURDAY, SEPTEMBER 25
Late Breaking Trials
ISAR-TEST-5: A Prospective Randomized Trial of Polymer-Free Sirolimus-/Probucol-Eluting Stents Compared to Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
HORIZONS-AMI: Three-Year Follow-up from a Prospective Randomized Trial of Antithrombin Strategies and Drug-Eluting Stents in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty
CRISTAL: A Prospective Randomized Trial of Sirolimus-Eluting Stents Compared to Balloon Angioplasty for Restenosis of Drug-Eluting Coronary Stents
First Report Investigations
BIOFREEDOM: A Prospective Randomized Trial of Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
AVIO: A Prospective Randomized Trial of Intravascular Ultrasound-Guided Compared to Angiography-Guided Stent Implantation in Complex Coronary Lesions
EXCELLENT: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
Media may apply for registration by clicking on:
http://www.tctconference.com/press/press-registration-form.html
Details on required press credentials can be found at:
http://www.tctconference.com/press/press-credentials-a-guidelines.html
To view the program update, visit:
http://www.tctconference.com/pdf/2010program-update.pdf
Receive updates on Twitter:
http://twitter.com/TCTConference
View related video content on YouTube:
http://www.youtube.com/user/TCTConference
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.
For more information, visit www.crf.org.
